Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fennec Pharmaceuticals Inc (NQ: FENC )

9.380 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 3.770 (2)
Ask (Size) 9.790 (2)
Prev. Close 9.380
Today's Range 9.380 - 9.380
52wk Range 6.300 - 11.92
Shares Outstanding 27,099,908
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
FENC stock results show that Fennec Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Earnings Scheduled For March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. 
Via Benzinga

Performance

YTD
-15.65%
-15.65%
1 Month
-14.73%
-14.73%
3 Month
-8.49%
-8.49%
6 Month
+37.94%
+37.94%
1 Year
+17.10%
+17.10%

More News

Read More
Fennec Pharmaceuticals's Earnings Outlook
Via Benzinga
Earnings Scheduled For November 6, 2023
Via Benzinga
Preview: Fennec Pharmaceuticals's Earnings
Via Benzinga
Analyst Ratings for Fennec Pharmaceuticals
Via Benzinga
Recap: Fennec Pharmaceuticals Q1 Earnings
Via Benzinga
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) Highlighted for Surprising Price Action
Via Investor Brand Network
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) Making Surprising Moves in Monday Session
Via Investor Brand Network
Earnings Outlook For Fennec Pharmaceuticals
Via Benzinga
Analyst Ratings for Fennec Pharmaceuticals
Via Benzinga
7 Biotech Stocks Sitting in the Sweet Spot
Via InvestorPlace
US Stocks Open Lower; Dow Dips 250 Points
Via Benzinga
Expert Ratings for Fennec Pharmaceuticals
Via Benzinga
What 4 Analyst Ratings Have To Say About Fennec Pharmaceuticals
Via Benzinga
4 Analysts Have This to Say About Fennec Pharmaceuticals
Via Benzinga
Where Fennec Pharmaceuticals Stands With Analysts
Via Benzinga
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
Via Benzinga
After Two FDA Rejections, Fennec Pharma Lead Drug Scores US Approval For Chemo-Induced Hearing Loss
Via Benzinga
Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022
Via Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
Via Benzinga
NASDAQ:FENC Long Term Shareholder Notice: Investigation over Possible Wrongdoing at Fennec Pharmaceuticals Inc.
Via SBWire
U.S. FDA accepts Fennec Pharma's New Drug Application (NDA) Resubmission for PEDMARK
Via Benzinga
NASDAQ:FENC Shareholder Notice: Deadline on April 11, 2022 in Lawsuit Against Fennec Pharmaceuticals Inc.
Via SBWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.